A Phase I Study to Evaluate Drug-Drug Interaction of TQ05105 Tablets
Overview
- Phase
- Phase 1
- Intervention
- TQ05105 tablets
- Conditions
- Myelofibrosis
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Enrollment
- 40
- Locations
- 1
- Primary Endpoint
- Elimination half-life (t1/2)
- Status
- Completed
- Last Updated
- 4 months ago
Overview
Brief Summary
This is a single-center, open, single-dose, self-controlled phase I clinical trial to evaluate the effects of metabolic enzyme inhibitors/inducers on in vivo metabolic and elimination of TQ05105 tablets, and the safety of metabolic enzyme inhibitors/inducers combined with TQ05105 tablets.
Investigators
Eligibility Criteria
Inclusion Criteria
- •At the time of signing the informed consent, males or females between 18 and 45 years of age;
- •Female weight ≥ 45 kg, male weight ≥ 50 kg, with a body mass index (BMI) between 19 and 26 kg/m
- •Subjects in good health, as determined by a medical history, vital signs, physical examination, 12-lead electrocardiogram (ECG) and clinical laboratory evaluations;
- •Subjects can comply with the study procedures, voluntarily participate in the study, and sign the informed consent in person.
Exclusion Criteria
- •Subjects: preexisting or existing circulatory system, endocrine system, nervous system, digestive system, respiratory system, genitourinary system, hematology, immunology, psychiatry and metabolic disorders or abnormalities, or related chronic or acute diseases, the investigator assesses that it is not appropriate to participate in the trial；
- •Subjects with Systemic/local acute infection before taking the study drug;
- •Subjects who have a history of specific allergies, or allergic conditions (such as allergies to two or more drugs, environments, or foods), or are known to be allergic to components or analogs of the study drug;
- •Subjects who have difficulty in swallowing or have any gastrointestinal disorder that affects drug absorption at the time of screening；
- •Subjects who cannot receive venous indwelling needle for blood sample collection；
- •Subjects who drank regularly in the 6 months prior to first dosing, such as those who drank more than 14 units of alcohol per week or who had a positive alcohol breath test at the time of screening；
- •Subjects who had a history of major surgery, or had taken the study drug, or had participated in other drug clinical trials within 3 months prior to initial dosing；
- •Subjects who donated blood or lost significant amounts of blood within 3 months prior to initial dosing；
- •Subjects who had used drugs within 3 months prior to first dosing, or tested positive for drugs, or had a history of drug abuse within 5 years prior to screening；
- •Subjects who smoked more than 5 cigarettes per day in the 3 months prior to initial dosing or who could not stop using any tobacco products during the trial；
Arms & Interventions
Itraconazole drug-durg interaction (DDI)
Itraconazole capsule: 0.2g once daily on Days 2 to Day 5; TQ05105 tablets: single oral dose on Days 1 and Day 5.
Intervention: TQ05105 tablets
Itraconazole drug-durg interaction (DDI)
Itraconazole capsule: 0.2g once daily on Days 2 to Day 5; TQ05105 tablets: single oral dose on Days 1 and Day 5.
Intervention: Itraconazole capsule
Rifampicin DDI
Rifampicin Capsule: 0.6g once daily on Days 2 to Day 9; TQ05105 tablets: single oral dose on Days 1 and Day 9.
Intervention: TQ05105 tablets
Rifampicin DDI
Rifampicin Capsule: 0.6g once daily on Days 2 to Day 9; TQ05105 tablets: single oral dose on Days 1 and Day 9.
Intervention: Rifampicin Capsule
Outcomes
Primary Outcomes
Elimination half-life (t1/2)
Time Frame: Up to 6 days.
The elimination half-life (t1/2) after oral dose of TQ05105 tablets and Itraconazole capsule.
Maximum plasma concentration (Cmax)
Time Frame: Up to 10 days.
Maximum plasma drug concentration after administration.
Time to reach Cmax (Tmax)
Time Frame: Up to 10 days.
Time to reach the maximum plasma concentration after administration.
Secondary Outcomes
- Occurrence of adverse events (AE)(Up to 30 days.)